Compare Stocks: DFTX, VTRS, JAZZ, and NBIX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DFTX Definium Therapeutics	$38.89 +3.1%	$43.01	$8.77 ▼ $49.70	$5.07B	2.23	1.56 million shs	1.75 million shs
JAZZ Jazz Pharmaceuticals	$245.80 +2.2%	$249.37	$123.88 ▼ $266.38	$15.61B	0.36	975,014 shs	422,888 shs
NBIX Neurocrine Biosciences	$156.22 -0.2%	$164.46	$122.14 ▼ $186.12	$15.92B	0.38	990,058 shs	890,854 shs
VTRS Viatris	$16.51 +0.8%	$16.80	$9.43 ▼ $18.39	$18.81B	0.89	6.84 million shs	12.17 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DFTX Definium Therapeutics	-0.68%	-0.71%	-7.77%	+52.44%	+304.39%
JAZZ Jazz Pharmaceuticals	-0.34%	-2.86%	-3.02%	+4.30%	+89.50%
NBIX Neurocrine Biosciences	+0.92%	-1.12%	-3.32%	-2.00%	+10.85%
VTRS Viatris	-0.73%	-3.31%	+0.61%	-0.61%	+59.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DFTX Definium Therapeutics	$38.89 +3.1%	$43.01	$8.77 ▼ $49.70	$5.07B	2.23	1.56 million shs	1.75 million shs
JAZZ Jazz Pharmaceuticals	$245.80 +2.2%	$249.37	$123.88 ▼ $266.38	$15.61B	0.36	975,014 shs	422,888 shs
NBIX Neurocrine Biosciences	$156.22 -0.2%	$164.46	$122.14 ▼ $186.12	$15.92B	0.38	990,058 shs	890,854 shs
VTRS Viatris	$16.51 +0.8%	$16.80	$9.43 ▼ $18.39	$18.81B	0.89	6.84 million shs	12.17 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DFTX Definium Therapeutics	-0.68%	-0.71%	-7.77%	+52.44%	+304.39%
JAZZ Jazz Pharmaceuticals	-0.34%	-2.86%	-3.02%	+4.30%	+89.50%
NBIX Neurocrine Biosciences	+0.92%	-1.12%	-3.32%	-2.00%	+10.85%
VTRS Viatris	-0.73%	-3.31%	+0.61%	-0.61%	+59.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DFTX Definium Therapeutics	3.00	Buy	$63.00	62.00% Upside
JAZZ Jazz Pharmaceuticals	3.00	Buy	$286.72	16.65% Upside
NBIX Neurocrine Biosciences	2.88	Moderate Buy	$201.09	28.72% Upside
VTRS Viatris	2.50	Moderate Buy	$18.57	12.49% Upside

Current Analyst Ratings Breakdown

Latest DFTX, VTRS, JAZZ, and NBIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	JAZZ Jazz Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$315.00 ➝ $337.00
9/11/2026	DFTX Definium Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$66.00
9/11/2026	NBIX Neurocrine Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$182.00 ➝ $183.00
9/10/2026	JAZZ Jazz Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$270.00 ➝ $271.00
9/9/2026	VTRS Viatris	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
9/9/2026	VTRS Viatris	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
9/8/2026	NBIX Neurocrine Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
9/8/2026	NBIX Neurocrine Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$198.00
9/8/2026	VTRS Viatris	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$15.00 ➝ $20.00
9/3/2026	VTRS Viatris	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
9/3/2026	NBIX Neurocrine Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$249.00 ➝ $253.00

(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	$3.36 per share	N/A
JAZZ Jazz Pharmaceuticals	$4.27B	3.74	$16.62 per share	14.79	$71.07 per share	3.46
NBIX Neurocrine Biosciences	$2.86B	5.55	$5.00 per share	31.24	$32.63 per share	4.79
VTRS Viatris	$14.30B	1.33	$7.44 per share	2.22	$12.77 per share	1.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DFTX Definium Therapeutics	-$183.79M	-$3.43	N/A	N/A	N/A	N/A	-84.01%	-63.66%	N/A
JAZZ Jazz Pharmaceuticals	-$356.15M	$14.50	10.41	11.08	0.22	20.45%	33.97%	13.02%	11/4/2026 (Estimated)
NBIX Neurocrine Biosciences	$478.60M	$6.82	21.63	16.51	0.73	20.91%	22.43%	15.64%	10/27/2026 (Estimated)
VTRS Viatris	-$3.51B	-$0.36	6.50	6.21	1.47	-2.79%	20.02%	8.02%	11/5/2026 (Estimated)

Latest DFTX, VTRS, JAZZ, and NBIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	DFTX Definium Therapeutics	-$0.55	-$1.44	-$0.89	-$1.44	N/A	N/A
8/6/2026	Q2 2026	VTRS Viatris	$0.6010	$0.69	+$0.0890	-$0.10	$3.68 billion	$3.76 billion
8/3/2026	Q2 2026	JAZZ Jazz Pharmaceuticals	$6.18	$5.71	-$0.47	$2.78	$1.11 billion	$1.21 billion
7/31/2026	Q2 2026	NBIX Neurocrine Biosciences	$1.65	$2.85	+$1.20	$1.39	$891.16 million	$959.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
VTRS Viatris	$0.48	2.91%	N/A	N/A	N/A

Latest DFTX, VTRS, JAZZ, and NBIX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/3/2026	VTRS Viatris	quarterly	$0.12	2.94%	8/21/2026	8/21/2026	9/16/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DFTX Definium Therapeutics	0.04	6.95	6.95
JAZZ Jazz Pharmaceuticals	0.69	1.78	1.58
NBIX Neurocrine Biosciences	N/A	1.87	1.75
VTRS Viatris	0.81	1.58	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DFTX Definium Therapeutics	27.91%
JAZZ Jazz Pharmaceuticals	89.14%
NBIX Neurocrine Biosciences	92.59%
VTRS Viatris	79.88%

Insider Ownership

Company	Insider Ownership
DFTX Definium Therapeutics	2.40%
JAZZ Jazz Pharmaceuticals	4.10%
NBIX Neurocrine Biosciences	4.60%
VTRS Viatris	0.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DFTX Definium Therapeutics	40	134.37 million	131.14 million	Optionable
JAZZ Jazz Pharmaceuticals	2,890	64.92 million	62.25 million	Optionable
NBIX Neurocrine Biosciences	2,000	101.65 million	96.97 million	Optionable
VTRS Viatris	30,000	1.15 billion	1.15 billion	Optionable

DFTX, VTRS, JAZZ, and NBIX Headlines

Recent News About These Companies

viatris inc. - VTRS

September 10 at 7:35 PM | foxbusiness.com

Leerink Partners initiates coverage of Viatris with outperform rating

September 10 at 9:34 AM | msn.com

Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive

September 9 at 6:03 PM | seekingalpha.com

Viatris Inc. : Leerink Partners réajuste son opinion à la hausse

September 9 at 1:02 PM | zonebourse.comZ

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?

September 9 at 10:40 AM | zacks.com

Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating

September 8 at 9:59 AM | marketscreener.comM

Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough?

August 29, 2026 | finance.yahoo.com

Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris

August 28, 2026 | proactiveinvestors.co.uk

3 Generic Drug Stocks to Watch Amid Improving Industry Trends

August 27, 2026 | zacks.com

Viatris' China Policy Concerns Overstated, UBS Says

August 19, 2026 | finance.yahoo.com

Here's Why Viatris (VTRS) is a Strong Value Stock

August 18, 2026 | zacks.com

Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Viatris posts Q2 beat; sells eye drug Tyrvaya to Harrow for up to $100M

August 6, 2026 | seekingalpha.com

Viatris (NASDAQ:VTRS) posts better-than-expected sales in Q2 CY2026

August 6, 2026 | msn.com

Viatris Inc. 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump

August 6, 2026 | zacks.com

Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

August 6, 2026 | zacks.com

Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates

August 6, 2026 | zacks.com

Viatris Reports Second-Quarter 2026 Financial Results

August 6, 2026 | prnewswire.com

Viatris (VTRS) Q2 earnings report preview: What to look for

August 5, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX, VTRS, JAZZ, and NBIX Company Descriptions

Definium Therapeutics NASDAQ:DFTX

$38.89 +1.16 (+3.07%)

As of 04:00 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Jazz Pharmaceuticals NASDAQ:JAZZ

$245.80 +5.32 (+2.21%)

Closing price 04:00 PM Eastern

Extended Trading

$250.00 +4.19 (+1.71%)

As of 07:30 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Neurocrine Biosciences NASDAQ:NBIX

$156.22 -0.35 (-0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$156.12 -0.09 (-0.06%)

As of 07:47 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Viatris NASDAQ:VTRS

$16.51 +0.13 (+0.79%)

Closing price 04:00 PM Eastern

Extended Trading

$16.60 +0.09 (+0.55%)

As of 07:30 PM Eastern

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DFTX, VTRS, JAZZ, and NBIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DFTX, VTRS, JAZZ, and NBIX Earnings

Compare Dividends

Latest DFTX, VTRS, JAZZ, and NBIX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DFTX, VTRS, JAZZ, and NBIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX, VTRS, JAZZ, and NBIX Company Descriptions

Definium Therapeutics NASDAQ:DFTX

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

Viatris NASDAQ:VTRS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DFTX, VTRS, JAZZ, and NBIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DFTX, VTRS, JAZZ, and NBIX Earnings

Compare Dividends

Latest DFTX, VTRS, JAZZ, and NBIX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DFTX, VTRS, JAZZ, and NBIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX, VTRS, JAZZ, and NBIX Company Descriptions

Definium Therapeutics NASDAQ:DFTX

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

Viatris NASDAQ:VTRS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools